Archive: January 2023

Immunotherapy Treatment Landscape for Patients With Endometrial Cancer: Current Evidence and Future Opportunities

Abstract: Endometrial cancer is the most common gynecologic cancer in the United States, with a rising incidence and mortality. Traditionally, systemic treatment has included combination platinum- […]

Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

Abstract: Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly […]

Beyond Factor Replacement Therapy: New and Experimental Agents for Hemophilia

H&O  What are the limitations of factor VIII administration to prevent and treat bleeding in hemophilia? AV  Factor VIII administration entails frequent intravenous infusions, which require […]

How We Treat Advanced Biliary Tract Cancers in the Second-Line Setting

Overview • Advanced biliary tract cancers are a group of rare and aggressive malignancies with a poor prognosis. • The effectiveness of cytotoxic chemotherapy is modest […]

Optimizing the Benefits of BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

H&O  Why is the B-cell maturation antigen (BCMA) a good target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? SL  BCMA is an important […]

Letter From the Editor: How We Win Against Cancer

Doctors frequently rely on metaphors to communicate complicated and technical biological concepts to patients. For cancer treatment, the metaphor of a battle or war has been […]

Tumor-Infiltrating Lymphocyte Therapy in Metastatic Melanoma

H&O What options are available for patients with metastatic melanoma that does not respond or has stopped responding to checkpoint inhibition and BRAF/MEK-targeted agents? JC No […]

Back to Archive